Clinical trial
Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With BTcP
Name
ZK06
Description
Breakthrough cancer pain (BTcP) is a common problem in patients with cancer. This is a phase IIa dose-response and safety study of inhaled fentanyl aerosol (25µg/dose) in Chinese patients with breakthrough cancer pain.
Trial arms
Trial start
2021-10-20
Estimated PCD
2023-03-15
Trial end
2023-04-27
Status
Completed
Phase
Early phase I
Treatment
Inhaled fentanyl aerosol
Participants were randomized to 6 BTP episodes, in which 4 BTP episodes were treated with inhaled fentanyl aerosol (with a starting dose of 25 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×25 µg) and 2 BTP episodes with placebo(0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence.
Arms:
Inhaled fentanyl aerosol
Placebo
Participants were randomized to 6 BTP episodes, in which 4 BTP episodes were treated with inhaled fentanyl aerosol (with a starting dose of 25 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×25 µg) and 2 BTP episodes with placebo(0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence.
Arms:
Placebo
Size
60
Primary endpoint
SPID30
at each episode of breakthrough pain, 30 minutes after first dose of study drug.
Eligibility criteria
Inclusion Criteria:
1. Age of 18 years or above
2. Subjects must be diagnosed with cancer.
3. Subjects must experience persistent pain associated with cancer, and the pain score assessed by NRS should be \<4 within 1week before screening.
4. In the past 7 days, the subject must experience an average of 1 to 4 episodes of breakthrough cancer pain per day,The breakthrough cancer pain score should be ≥4 assessed by NRS
5. ECOG status of 0 to 2.
6. Subjects must consent to take adequate contraception during the study and 1 months after the study. Women of childbearing potential must show negative in the pregnancy test before dosing.
7. The subject must be able to understand the requirements of the study and provide a written informed consent.
Exclusion Criteria:
1. History or suspected allergies to fentanyl.
2. HGB \< 80 g/L, NEUT ≤1.0 × l09/L, PLT ≤50 × l09/L；ALT and AST higher than 3 times of ULN;total bilirubin and Cr higher than 1.5 times of ULN;PaO2 \<95%;FEV1/FVC\<70% and FEV1 accounted for less than 80% of the predicted value.
3. Any uncontrolled disease (e.g., severe mental, neurological, infectious, cardiovascular, respiratory and other systemic diseases).
4. Tumor infiltration to central nervous system.
5. Subjects are not able to slef evaluate pain intensity using NRS
6. Receive surgery in past 3 weeks
7. Treatment with any form of radiotherapy winth 1week prior to study entry that could alter pain or response to pain medication.
8. Taking monoamine oxidase inhibitors(MAOIs), CYP3A4 inhibitors or inducers within 14 days of the screening
9. Participated in other clinical trials in past 1months.
10. Pregnancy and breast-feeding women, women of childbearing age ready to conceive, and pregnancy test positive.
11. Other conditions that may affect the informed consent, compliance with the protocol, study results and safety of the subject.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'CROSSOVER', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 60, 'type': 'ACTUAL'}}
Updated at
2024-06-12
1 organization
1 product
1 drug
1 indication
Organization
Lee's Pharmaceutical LimitedProduct
Inhaled fentanyl aerosolIndication
Breakthrough Cancer PainDrug
Varlilumab